Table 3.
Characteristics of the studies evaluating the association between GSTT1 polymorphisms and treatment response.
| Study | Year | Ethnicity/country | Chemotherapeutic drugs | Poor response present/null | Good response present/null | OR (95% CI) | Weight % | P-value | Study quality |
|---|---|---|---|---|---|---|---|---|---|
| Jia et al. [19] | 2016 | East-Asian/China | DDP | 83/96 | 28/37 | 1.142 (0.645, 2.024) | 17.21 | 0.65 | 7 |
| Xiao et al. [2] | 2016 | East-Asian/China | DDP | 68/51 | 77/66 | 1.143 (0.700, 1.865) | 23.41 | 0.59 | 7 |
| Chen et al. [20] | 2016 | East-Asian/China | DDP | 118/88 | 37/41 | 1.486 (0.881, 2.507) | 17.91 | 0.14 | 8 |
| Han Ba [11] | 2016 | East-Asian/China | DDP+ DOC/DDP+ NVB/Pt+ GEM | 42/40 | 35/39 | 1.170 (0.624, 2.195) | 14.02 | 0.29 | 9 |
| Wu et al. [21] | 2015 | East-Asian/China | DDP | 92/67 | 69/54 | 1.075 (0.668, 1.729) | 25.61 | 0.77 | 7 |
| Kalikaki et al. [25] | 2009 | Caucasian/Greece | Pt/Pt-TXT-based | 73/4 | 33/2 | 1.106 (0.193, 6.342) | 1.84 | 0.72 | 8 |
| M-H pooled OR | 1.190 (0.941, 1.504) | 100 | 0.146 | ||||||
OR – odds ratio; 95% CI – 95%confidence interval; DDP – cisplatin; GEM – gemcitabine; NVB – vinorelbine; PEM – pemetrexed; TAX – taxol/paclitaxel; TXT – taxetere; DOC – docetaxel; VP-16 – etoposide; MMC – mitomycin; IFO – ifosfamide; VLB – vinblastine; Pt – platinum.